<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02996019</url>
  </required_header>
  <id_info>
    <org_study_id>GX29504</org_study_id>
    <nct_id>NCT02996019</nct_id>
  </id_info>
  <brief_title>A Study to Compare Pharmacokinetics (PK) of Etrolizumab Administered Subcutaneously by a Prefilled Syringe With Needle Safety Device (PFS-NSD) or an Auto-injector (AI)</brief_title>
  <official_title>A Randomized, Open-Label, 2-Part, 2-Arm, Parallel-Group, Single-Dose, Multi-Center Study in Healthy Subjects to Investigate the Comparability of Pharmacokinetics of Etrolizumab Administered Subcutaneously by a Prefilled Syringe With Needle Safety Device or an Auto-Injector</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <brief_summary>
    <textblock>
      This is a randomized, 2-part, 2-arm, open-label, parallel-group, multi-center study to&#xD;
      compare the PK of etrolizumab administered subcutaneously by an AI (test device) or a PFS-NSD&#xD;
      (reference device) in healthy participants. The study will comprise a pilot cohort (Part 1)&#xD;
      to estimate the geometric mean ratio (GMR) and variability of the maximum observed&#xD;
      concentration (Cmax) and area under the concentration-time curve (AUC) to confirm or&#xD;
      determine the sample size for the pivotal cohort (Part 2). The pivotal cohort will&#xD;
      demonstrate exposure comparability of Cmax, AUC from Hour 0 to the last measurable&#xD;
      concentration (AUClast), and AUC from Hour 0 to extrapolated infinite time (AUC0-inf), values&#xD;
      for a single dose of etrolizumab administered subcutaneously either by the AI or the PFS-NSD.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 7, 2016</start_date>
  <completion_date type="Actual">April 9, 2018</completion_date>
  <primary_completion_date type="Actual">April 9, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Cmax of Etrolizumab</measure>
    <time_frame>Predose (0 hours) and 6 hours postdose on Day 1, on Days 2, 4, 6, 8, 11, 15, 29, 43, 57, and at end of study (Day 71) or early discontinuation (up to Day 71)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: AUClast of Etrolizumab</measure>
    <time_frame>Predose (0 hours) and 6 hours postdose on Day 1, on Days 2, 4, 6, 8, 11, 15, 29, 43, 57, and at end of study (Day 71) or early discontinuation (up to Day 71)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: AUC0-inf of Etrolizumab</measure>
    <time_frame>Predose (0 hours) and 6 hours postdose on Day 1, on Days 2, 4, 6, 8, 11, 15, 29, 43, 57, and at end of study (Day 71) or early discontinuation (up to Day 71)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Ratio of AUClast to AUC0-inf (AUCR) of Etrolizumab</measure>
    <time_frame>Predose (0 hours) and 6 hours postdose on Day 1, on Days 2, 4, 6, 8, 11, 15, 29, 43, 57, and at end of study (Day 71) or early discontinuation (up to Day 71)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Cmax of Etrolizumab</measure>
    <time_frame>Predose (0 hours) and 6 hours postdose on Day 1, on Days 2, 4, 6, 8, 11, 15, 29, 43, 57, and at end of study (Day 71) or early discontinuation (up to Day 71)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: AUClast of Etrolizumab</measure>
    <time_frame>Predose (0 hours) and 6 hours postdose on Day 1, on Days 2, 4, 6, 8, 11, 15, 29, 43, 57, and at end of study (Day 71) or early discontinuation (up to Day 71)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: AUC0-inf of Etrolizumab</measure>
    <time_frame>Predose (0 hours) and 6 hours postdose on Day 1, on Days 2, 4, 6, 8, 11, 15, 29, 43, 57, and at end of study (Day 71) or early discontinuation (up to Day 71)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1: Time to Maximum Observed Concentration (tmax) of Etrolizumab</measure>
    <time_frame>Predose (0 hours) and 6 hours postdose on Day 1, on Days 2, 4, 6, 8, 11, 15, 29, 43, 57, and at end of study (Day 71) or early discontinuation (up to Day 71)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: tmax of Etrolizumab</measure>
    <time_frame>Predose (0 hours) and 6 hours postdose on Day 1, on Days 2, 4, 6, 8, 11, 15, 29, 43, 57, and at end of study (Day 71) or early discontinuation (up to Day 71)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Apparent Terminal Elimination Half-Life (t1/2) of Etrolizumab</measure>
    <time_frame>Predose (0 hours) and 6 hours postdose on Day 1, on Days 2, 4, 6, 8, 11, 15, 29, 43, 57, and at end of study (Day 71) or early discontinuation (up to Day 71)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: t1/2 of Etrolizumab</measure>
    <time_frame>Predose (0 hours) and 6 hours postdose on Day 1, on Days 2, 4, 6, 8, 11, 15, 29, 43, 57, and at end of study (Day 71) or early discontinuation (up to Day 71)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: AUCR of Etrolizumab</measure>
    <time_frame>Predose (0 hours) and 6 hours postdose on Day 1, on Days 2, 4, 6, 8, 11, 15, 29, 43, 57, and at end of study (Day 71) or early discontinuation (up to Day 71)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Adverse Events</measure>
    <time_frame>Part 1 and 2: Baseline up to Day 71</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) Against Etrolizumab</measure>
    <time_frame>Part 1 and 2: Baseline up to Day 71</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">180</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Part 1: Etrolizumab AI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single dose of etrolizumab via subcutaneous (SC) injection using the AI on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Etrolizumab PFS-NSD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive a single dose of etrolizumab via SC injection using the PFS-NSD on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Etrolizumab AI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single dose of etrolizumab via SC injection using the AI on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Etrolizumab PFS-NSD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive a single dose of etrolizumab via SC injection using the PFS-NSD on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etrolizumab</intervention_name>
    <description>Etrolizumab will be administered at a dose of 105 milligrams (mg).</description>
    <arm_group_label>Part 1: Etrolizumab AI</arm_group_label>
    <arm_group_label>Part 1: Etrolizumab PFS-NSD</arm_group_label>
    <arm_group_label>Part 2: Etrolizumab AI</arm_group_label>
    <arm_group_label>Part 2: Etrolizumab PFS-NSD</arm_group_label>
    <other_name>RO5490261</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Auto-Injector (AI)</intervention_name>
    <description>The pre-filled AI will be used to administer etrolizumab.</description>
    <arm_group_label>Part 1: Etrolizumab AI</arm_group_label>
    <arm_group_label>Part 2: Etrolizumab AI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Prefilled Syringe With Needle Safety Device (PFS-NSD)</intervention_name>
    <description>The PFS-NSD will be used to administer etrolizumab.</description>
    <arm_group_label>Part 1: Etrolizumab PFS-NSD</arm_group_label>
    <arm_group_label>Part 2: Etrolizumab PFS-NSD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Within the body weight range of 60 to 100 kilograms, inclusive (for the pivotal cohort&#xD;
             [Part 2] only)&#xD;
&#xD;
          -  Within body mass index (BMI) range 18.0 to 30.0 kilograms per square meter (kg/m^2),&#xD;
             inclusive&#xD;
&#xD;
          -  In good health, determined by no clinically significant findings from medical history,&#xD;
             physical examination, 12-lead electrocardiogram (ECG), and vital signs&#xD;
&#xD;
          -  Females will be non-pregnant, non-lactating, and either postmenopausal (at least 12&#xD;
             months of non-therapy-induced amenorrhea)/surgically sterile (e.g., tubal ligation,&#xD;
             hysterectomy) for at least 90 days prior to enrolment, or agree to remain&#xD;
             abstinent/use a highly effective method of contraception for at least 24 weeks after&#xD;
             study drug administration&#xD;
&#xD;
          -  Males will either be sterile or agree to remain abstinent/use a highly effective&#xD;
             method of contraception for at least 24 weeks after study drug administration. Male&#xD;
             participants will refrain from sperm donation from Check-in (Day -1) until 24 weeks&#xD;
             following study drug administration&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any prior treatment with etrolizumab or other anti-integrin agents (including&#xD;
             natalizumab, vedolizumab, and efalizumab)&#xD;
&#xD;
          -  Any prior treatment with anti-mucosal addressin cell adhesion molecule 1&#xD;
             (anti-MAdCAM-1) agents&#xD;
&#xD;
          -  Any prior treatment with rituximab&#xD;
&#xD;
          -  Received intravenous corticosteroids within 30 days prior to Screening&#xD;
&#xD;
          -  Use of agents that deplete B or T cells (e.g., alemtuzumab, rituximab, or visilizumab)&#xD;
             within 12 months prior to randomization&#xD;
&#xD;
          -  Any prior immunosuppressive agents (including cyclosporine, tacrolimus, sirolimus,&#xD;
             mycophenolate mofetil)&#xD;
&#xD;
          -  Chronic nonsteroidal anti-inflammatory drug (NSAID) use&#xD;
&#xD;
          -  Use of any prescription medications/products within 14 days prior to Check in (Day -1)&#xD;
&#xD;
          -  History of demyelinating disease&#xD;
&#xD;
          -  Neurological conditions or diseases&#xD;
&#xD;
          -  History of cancer&#xD;
&#xD;
          -  History of alcoholism or drug addiction within less than (&lt;) 1 year prior to Screening&#xD;
&#xD;
          -  History of active or latent tuberculosis (TB), regardless of treatment history&#xD;
&#xD;
          -  History of recurrent opportunistic infections and/or history of severe disseminated&#xD;
             viral infections&#xD;
&#xD;
          -  Positive for human immunodeficiency virus (HIV) antibody&#xD;
&#xD;
          -  Any current or recent signs or symptoms of infection&#xD;
&#xD;
          -  Pregnant or lactating&#xD;
&#xD;
          -  Hospitalized within 4 weeks prior to and during Screening&#xD;
&#xD;
          -  History of organ transplant&#xD;
&#xD;
          -  Presence of skin rash at Screening or history of other skin disorders&#xD;
&#xD;
          -  Tattoos, scars, chronic rashes, or sunburn in the area of the designated injection&#xD;
             site&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Research Unit - Daytona</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Covance Clinical Research Unit Inc.; Covance Gfi Research</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Covance Research Unit - Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75247</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Covance Clinical Research Unit, Inc</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>December 14, 2016</study_first_submitted>
  <study_first_submitted_qc>December 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2016</study_first_posted>
  <last_update_submitted>November 30, 2018</last_update_submitted>
  <last_update_submitted_qc>November 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etrolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

